Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.